文献速递临床试验与 GCP基础与转化研究

二甲双胍治疗未破裂椎基底动脉夹层动脉瘤(METTLE):双盲随机对照试验研究方案

Metformin for the treatment of unruptured vertebrobasilar dissecting aneurysm (METTLE): study protocol for a double-blinded randomised controlled trial.
PubMed 文献 · Trials · 2025-12-06

本研究为多中心、前瞻性、随机、对照、盲法临床试验,计划从中国3家医院招募60例未破裂椎基底动脉夹层动脉瘤患者,按1:1随机分配至二甲双胍组或安慰剂组(每组30例),分别口服250 mg二甲双胍或安慰剂每日两次,持续6个月。主要结局为高分辨率血管壁成像(HR-VWI)测量的动脉瘤壁炎症变化,次要结局包括动脉瘤形态、典型影像征象和炎症生物标志物变化。

要点

  • 纳入60例未破裂椎基底动脉夹层动脉瘤患者,1:1随机至二甲双胍250 mg或安慰剂每日两次口服,持续6个月。
  • 主要结局为HR-VWI测量的动脉瘤壁炎症变化,次要结局包括动脉瘤形态、典型影像征象和炎症生物标志物。
  • 研究为多中心、前瞻性、随机、对照、盲法临床试验,招募自2024年5月开始,预计2025年12月结束。

核心结论

  • 本研究旨在评估二甲双胍降低椎基底动脉夹层动脉瘤患者动脉瘤壁炎症(以HR-VWI测量)的能力,并可能为未破裂椎基底动脉夹层动脉瘤揭示新的治疗方式。

研究设计与样本

  • 多中心、前瞻性、随机、对照、盲法临床试验,从中国3家医院竞争性招募60例符合纳入/排除标准的未破裂椎基底动脉夹层动脉瘤患者。
  • 患者按1:1随机分配至治疗组或安慰剂组(每组30例),分别口服250 mg二甲双胍或安慰剂每日两次,持续6个月。
  • 患者招募于2024年5月开始,预计2025年12月结束。
  • 方案已获北京天坛医院伦理委员会批准(批准号KY2023-188-02),所有患者参与前需提供书面知情同意。
  • 试验注册号NCT06405971,注册日期2024年5月9日。

关键数值与推荐

  • 主要结局为HR-VWI测量的椎基底动脉夹层动脉瘤壁炎症变化。
  • 次要结局为椎基底动脉夹层动脉瘤形态、典型影像征象和炎症生物标志物的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 既往关于二甲双胍治疗颅内动脉瘤的研究均在动物中进行,缺乏人体前瞻性临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vertebrobasilar dissecting aneurysm (VBDA) has high morbidity and mortality rates, and it is an important cause of stroke in young and middle-aged adults. Previous studies have shown that aneurysm wall inflammation is a major factor contributing to the high risk of aneurysm growth and rupture. Metformin inhibits inflammation and may be a suitable candidate drug for VBDA. Here, we report the protocol for a study designed to evaluate the ability of metformin to reduce the degree of aneurysm wall inflammation in patients with VBDA, as measured by high-resolution vessel wall imaging (HR-VWI). METHODS: The study is a multicentre, prospective, randomised, controlled, and blinded clinical trial. Sixty patients with unruptured VBDA who meet the inclusion/exclusion criteria will be recruited competitively from three hospitals in China. Patient recruitment began in May 2024 and is expected to end in December 2025. The patients will be randomised (1:1) to treatment or placebo (n = 30 in each group), receiving either 250-mg metformin or placebo orally twice per day for 6 months. The primary outcome will be the change in VBDA wall inflammation measured by HR-VWI. The secondary outcomes will be changes in VBDA morphology, typical imaging signs, and inflammatory biomarkers. DISCUSSION: Previous studies on metformin for the treatment of intracranial aneurysms have been performed in animals. However, prospective clinical studies in humans are lacking. Therefore, this study will provide insights into the anti-inflammatory effects of metformin in inhibiting VBDA growth and rupture and may reveal a new treatment modality for unruptured VBDA. The protocol has been approved by the Ethics Committee of Beijing Tiantan Hospital (approval no. KY2023-188-02). All patients will be required to provide written informed consent prior to participation. The results of the study will be disseminated through peer-reviewed journals and at relevant academic conferences. TRIAL REGISTRATION: NCT06405971. Registered on May 9, 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dong L, Xu Z, Li Y, et al. Metformin for the treatment of unruptured vertebrobasilar dissecting aneurysm (METTLE): study protocol for a double-blinded randomised controlled trial. Trials. 2025. PMID: 41351119. doi:10.1186/s13063-025-09348-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。